A potent class of DNA-damaging agents, natural product bis-intercalator depsipeptides
(NPBIDs), was evaluated as ultrapotent payloads for use in antibody–drug conjugates …

Antibody–drug conjugates (ADCs) are emerging therapeutic agents in the treatment of
cancer, and various conjugation strategies and chemical linkers have been developed to …

Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that
currently combines the selectivity of monoclonal antibodies with the potency of a payload …

[Fam-] trastuzumab deruxtecan (DS-8201a) is a HER2 (ERBB2)-targeting antibody-drug
conjugate, composed of a HER2-targeting antibody and a topoisomerase I inhibitor …

Antibody–drug conjugates (ADC) are designed to selectively bind to tumor antigens via the
antibody and release their cytotoxic payload upon internalization. Controllable payload …

Background: Native mass spectrometry (nMS) approaches appear attractive to complement
bottom-up strategies traditionally used in biopharmaceutical industries thanks to their quite …

Antibody-drug conjugates (ADCs) have demonstrated a great therapeutic potential against
cancer due to their target specificity and cytotoxicity. To exert a maximum therapeutic effect …

Herein we report the use of pyridazinediones to functionalise the native solvent accessible
interstrand disulfide bonds in trastuzumab with monomethyl auristatin E (MMAE). This …

Antibody–drug conjugates (ADCs) have a significant impact toward the treatment of cancer,
as evidenced by the clinical activity of the recently approved ADCs, brentuximab vedotin for …

Antibody–drug conjugates (ADCs) have emerged as valuable targeted anticancer
therapeutics with at least 11 approved therapies and over 80 advancing through clinical …